Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.76 |
| ▸ | RAB9A | P51151 | 11/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.76 |
| ▸ | HPGD | P15428 | 7/20 | 0.76 |
| ▸ | CASP3 | P42574 | 3/20 | 0.76 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.76 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.76 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15681413 | 0.94 | SMN1; SMN2 (0.88) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL12408905 | 0.91 | NPC1 (0.84) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL19601392 | 0.90 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL11551873 | 0.89 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL12304347 | 0.89 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL10125852 | 0.89 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL17585007 | 0.88 | RAB9A (0.78) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL152658 | 0.86 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL19601391 | 0.86 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL29362501 | 0.86 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074312-A1 | PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| WO-2023182775-A1 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING SAME | 에스에프씨 주식회사 | 2023-09-28 | — | — | WO | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-109265409-B | Synthesis method of 2-substituted benzoxazole, 2-substituted benzothiazole and derivatives thereof | 重庆医科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-108484517-B | Benzoxazole compound and synthesis method thereof | 信阳师范学院 | 2021-04-27 | — | — | CN | disclosed |
| US-20210095196-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2019078692-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2019-04-25 | — | — | WO | disclosed |
| CN-109265409-A | A kind of synthetic method of the benzoxazoles that 2- replaces and benzothiazole and its derivative that 2- replaces | 重庆医科大学 | 2019-01-25 | — | — | CN | disclosed |
| CN-109180590-A | A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free | 福建医科大学 | 2019-01-11 | — | — | CN | disclosed |
| US-20180223049-A1 | SILICONE-MODIFIED POLYBENZOXAZOLE RESIN AND MAKING METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2746272-A1 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2011021726-A2 | NITROGEN-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
| EP-0479161-A1 | Synthesis of heterocyclic compounds | EASTMAN CHEMICAL COMPANY (US) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074312-A1 | PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | MCM6, MCM2, SOD1 | NPC1 2193/4885RAB9A 1874/4885SMN1; SMN2 1695/4885 |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | NPC1 3859/4885RAB9A 2198/4885SMN1; SMN2 3262/4885 |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | NPC1 1655/4885RAB9A 2423/4885SMN1; SMN2 4214/4885 |
| US-20210095196-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SSB, RO60, OSBP | NPC1 2361/4885RAB9A 428/4885SMN1; SMN2 4645/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | NPC1 1869/4885RAB9A 3819/4885SMN1; SMN2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.